Telix Pharmaceuticals Limited (ASX:TLX) Reports $186M Q1 Revenue
Financial Performance
Telix Pharmaceuticals Limited (ASX:TLX) reported unaudited Q1 2025 revenue of approximately $186 million, marking a 62% increase year-on-year and a 31% rise quarter-over-quarter. Revenue included $151 million from global sales of Illuccix®, up 35% YoY, and $33 million from RLS Radiopharmacies following the acquisition completed in January 2025.
Guidance and Future Outlook
The company reaffirmed its FY 2025 revenue guidance of $770 million to $800 million, reflecting sales in jurisdictions with marketing authorisation and 11 months of RLS revenue. Telix also expects a 20% to 25% year-over-year increase in R&D expenditures for FY 2025 compared to FY 2024.
Executive Comments
Telix Managing Director and Group CEO, Dr Christian Behrenbruch, stated, “Illuccix has continued its momentum, gaining market share and maintaining price stability in a competitive landscape. Telix is the only company with two FDA-approved PSMA-PET imaging agents – Illuccix and Gozellix – enabling us to broaden patient reach and maximise choice for our customers. The expansion of our commercial portfolio and launches of Illuccix into new international markets provides a foundation to diversify and grow revenue globally, while we continue to deliver on multiple catalysts in our pipeline. This quarter also includes the first two months of revenue from RLS since completion of our acquisition, highlighting its potential as a platform to drive further growth. This strategic acquisition has significantly expanded our manufacturing footprint in the U.S., which we believe is an increasingly important consideration amid changing global trade dynamics.”
Motley Fool contributor Aaron Shaw has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
